B & T Cell-Mediated Autoimmune Disease Drug Development Summit 2022

The 3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit is the only industry-led forum focused on the therapeutic opportunity of drugs directed against B-cell, plasma cell, and T-cell targets in autoimmunity.

Several drug approvals for B-cell directed therapies have made waves in autoimmune drug development. As investment and industry momentum increases, this summit will once again unite the movers and shakers of the B&T cell-mediated autoimmune space with the likes of Pfizer, Nurix, Regeneron, Gossamer Bio and more!

Attending this summit is a unique opportunity to be involved in interactive discussions on:

• Overcoming challenges of heterogeneity of disease models and demonstrating B cell activation in tissues
• Emerging therapies including B-cell specific therapies, tolerizing approaches, small molecule drugs, engineered cell immunotherapy, B&T cell checkpoint targeting, FcRn inhibition, as well as PROTAC/degrader approaches
• Therapeutic opportunities across both peripheral and tissue specific autoimmune diseases
• Overcoming clinical challenges of treating B&T cell mediated autoimmune diseases through combinatorial regimens that target T-cell costimulation, leveraging autoantibody signatures to identify patient responders and discussing autoimmune disease biomarkers

New for 2022 is the pre-conference workshop day with a deep dive on T-Reg cells and type 1 diabetes and more interactive panel discussions than ever
before! As the space grapples with translational and early clinical drug development challenges, join this comprehensive forum 80+ key leaders and decision-makers to harness the immune system and conquer B&T cell mediated autoimmune diseases.

Speakers: Stephen Miller, Professor of Microbiology- Immunology, Northwestern University, Ryan Rountree, Chief Scientific Officer, Nurix Therapeutics, Rogier Thurlings, Rheumatologist, Radboud University Medical Centre, Dominic Borie, Chief Executive Officer, Kyverna Therapeutics, Kristen Taylor Meadows, Senior Director, Biology, Gossamer Bio, Aaron Winkler, Immune Tolerance Lead, Inflammation & Immunology, Pfizer, Chen Wanjun, Principle National Investigator, National Institute of Health, Veronica Campbell, Director, Immunology, Kymera Therapeutics, Evelyn Peelen, Senior Manager Translational Pharmacology, Immunic Therapeutics, Adam Elhofy, Chief Medical Officer, COUR Pharmaceuticals, Paul Belmonte, Field Medical Scientist, Provention Bio, Courtney Crane, Senior Vice President, Research, Mozart Therapeutics, Fabien Depuis, Director, Discovery Research, GentiBio, Randolf Noelle, Professor of Microbiology & Immunology, Dartmouth Medical School, Thomas Tedder, Alter E. Geller Professor for Research in Immunology Departments of Immunology & Pediatrics, Duke University, Simi Ahmed, Senior Vice President, Strategic Partnerships, New York Stem Cell Foundation, Robert Axtell, Associate Member, Oklahoma Medical Research Foundation, James Moon, Co-Founder & Chief Scientific Officer, EVOQ Therapeutics, Professor of Pharmaceutical Sciences, University of Michigan, Andre Limnander, Associate Director, Immunology & Inflammation, Regeneron, Matthias von Herrath, Senior Vice President & Chief Medical Officer, Novo Nordisk

Others Details

Brochure https://go.evvnt.com/1096486-1?pid=6581